Clinical Trial Update: Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis [Phase 2]

View source ↗

Summary

Phase 2 trial of etrasimod (APD334) for primary biliary cholangitis was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Etrasimod (etrasimod)

Snippet

Sponsor: Arena Pharmaceuticals | Conditions: Primary Biliary Cholangitis | Phase 2 | Status: TERMINATED | Results posted: 2022-03-24